Mushrooms and Remyelination: Cross-Species MS Research

Mushrooms & Multiple Sclerosis

4 species tested head-to-head

One 2022 mouse study fed four medicinal mushrooms into the same MS model and measured three endpoints separately. The species did not line up the same way on each one — and the mushroom with the strongest remyelination mechanism was the one that missed the motor endpoint.

Yamashina et al., Int J Med Mushrooms, 2022; Huang et al., Scientific Reports, 2021; Zhang et al., Chinese Medicine, 2026

OPCs → myelin

Lion's Mane mycelium matured myelin-producing cells and raised myelin basic protein in culture, in cerebellar slices, and in the brains of neonatal rat pups given it orally (Huang 2021)

4 species, 3 endpoints

the cuprizone MS mouse model in Yamashina 2022 — still the only head-to-head test of multiple mushroom species in an MS-mimicking demyelination model

Reishi cleared both

Ganoderma is the only species to show benefit in both the chemical (cuprizone) and autoimmune (EAE) rodent MS models, despite having no remyelination mechanism

Yamashina et al., Int J Med Mushrooms, 2022; Huang et al., Scientific Reports, 2021; Zhang et al., Chinese Medicine, 2026

View as image ↗

Multiple sclerosis strips the insulation from nerve fibers. The insulation is myelin, a protein-rich sheath that wraps around neurons and allows electrical signals to travel fast and without loss. When myelin is destroyed, signals misfire, slow, or stop entirely. That is the physical basis for the numbness, weakness, vision problems, and fatigue that MS patients experience.

The brain has a built-in repair mechanism: oligodendrocyte precursor cells (OPCs) circulate through the nervous system and can, under the right conditions, mature into the specialized cells that rebuild myelin sheaths. The problem is that this natural repair process frequently fails in MS, especially in progressive forms of the disease. Most existing MS drugs slow the immune attacks on myelin but do not actively support the repair process.

That gap is why remyelination research attracts attention, and why a set of preclinical studies on medicinal mushrooms has begun to address it. The research asks a specific question: can mushroom compounds support the cells and biological processes involved in rebuilding myelin, not just slow the attack on existing myelin?

This article covers the cross-species evidence for that question. For broader MS immune modulation context, see mushrooms and multiple sclerosis: immune modulation and remyelination. For brain health context, this cluster connects to the mushrooms and cognitive aging guide.

Why Remyelination Is a Different Target Than Controlling MS Symptoms

To understand why mushroom remyelination research is meaningful, it helps to distinguish between two completely different treatment goals in MS.

The first goal is reducing inflammatory attacks. Most disease-modifying therapies (DMTs), including interferon-beta, natalizumab, and ocrelizumab, work by suppressing or redirecting the immune response that drives relapse events. They prevent new attacks on myelin. They are effective at this. They do not repair the damage that has already accumulated.

The second goal is remyelination: rebuilding the myelin that has been destroyed. If successful, remyelination could restore nerve function in already-damaged pathways, not just prevent future damage. It would be qualitatively different from symptom management. No approved drug currently does this reliably in humans; remyelination remains one of the most active areas of MS research.

Mushroom research enters this picture through a specific cellular pathway. Myelin is produced by oligodendrocytes, highly specialized cells in the brain and spinal cord. Mature oligodendrocytes do not divide to replace themselves. When they are destroyed in MS, repair depends on OPCs, a pool of precursor cells that can mature into new oligodendrocytes. The OPC system has limited capacity and often fails under the inflammatory conditions of MS.

The specific question mushroom research has begun to answer: can mushroom compounds support OPC maturation, or directly stimulate myelination in ways that could assist this natural repair process?^[2]

The 2022 MS Mouse Study: Four Species, Three Endpoints, Different Answers

The most clinically proximate preclinical evidence in this field comes from Yamashina et al.'s 2022 study, and it is worth examining closely because the way it usually gets summarized is wrong.

The team used a cuprizone-induced demyelination model, the standard laboratory tool for studying MS-like myelin loss in animals. Cuprizone is a chemical that, when fed to mice over several weeks, kills mature oligodendrocytes and causes the myelin sheaths they maintain to degrade. The resulting pattern mirrors aspects of progressive MS rather than the relapse-remitting pattern driven by immune attacks. The model allows researchers to measure myelin loss directly, in a controlled setting.

The design detail that matters: mice were fed a powdered diet containing 5% of each mushroom alongside the cuprizone diet for 5 weeks, timed to coincide with peak demyelination.^[1] These were whole dried fruiting bodies incorporated into food, not concentrated extracts and not isolated compounds. That matters for interpretation: a 5%-of-diet dose is enormous relative to any human supplement regimen, and it tells you nothing about whether a capsule of extract would do the same thing.

The team measured three things separately: body weight, motor function via rotarod, and myelin levels via Black-Gold II staining. The results did not come out the same across species.

Yamashina 2022 — Endpoint by Endpoint

The Four Species Did Not Perform the Same Way

Mice were fed a powdered diet containing 5% of each mushroom alongside cuprizone for 5 weeks. Three endpoints were measured separately. Summaries that report one pooled result hide the two cells that matter most.

Species fed at 5% of diet	Weight-loss recoveryBody weight	Motor function improvedRotarod	Demyelination suppressedBlack-Gold II stain
Pleurotus eryngiiKing oyster	Not reported	Significant	Significant
Ganoderma lucidumReishi	Significant	Significant	Significant
Flammulina velutipesEnoki	Not reported	Significant	Significant
Hericium erinaceusLion's Mane	Significant	Not reported	Significant

Pleurotus eryngii

King oyster

Weight-loss recoveryNot reported

Motor function improvedSignificant

Demyelination suppressedSignificant

Ganoderma lucidum

Reishi

Weight-loss recoverySignificant

Motor function improvedSignificant

Demyelination suppressedSignificant

Flammulina velutipes

Enoki

Weight-loss recoveryNot reported

Motor function improvedSignificant

Demyelination suppressedSignificant

Hericium erinaceus

Lion's Mane

Weight-loss recoverySignificant

Motor function improvedNot reported

Demyelination suppressedSignificant

Ganoderma lucidum — Only species to hit all three endpoints.

Hericium erinaceus — Only species to miss the motor endpoint.

“Not reported” means the paper did not report a significant effect for that species on that endpoint. It is not evidence of no effect — the study was not powered to establish absence. But it does mean the confident claim that Lion’s Mane “preserved motor function” in this model is not what the paper says.

Source: Yamashina et al., International Journal of Medicinal Mushrooms, 2022 [ref 1]. Cuprizone-induced demyelination model, C57BL/6 mice, 5 weeks.

All four species — Pleurotus eryngii (king oyster), Ganoderma lucidum (Reishi), Flammulina velutipes (enoki), and Hericium erinaceus (Lion's Mane) — effectively suppressed cuprizone-induced demyelination. But only P. eryngii, G. lucidum, and F. velutipes significantly improved motor dysfunction. Lion's Mane, the species with by far the strongest mechanistic case for remyelination, is the one species of the four that did not show a significant motor benefit. Reishi and Lion's Mane were the two that recovered weight loss.

Anchor Study

Yamashina et al. (2022) · International Journal of Medicinal Mushrooms

Population

C57BL/6 mice with cuprizone-induced demyelination

Intervention

Powdered diet containing 5% dried fruiting bodies of each species, fed 5 weeks alongside cuprizone

Comparator

Cuprizone diet without mushroom supplementation

Finding

All four species (P. eryngii, G. lucidum, F. velutipes, H. erinaceus) suppressed demyelination on Black-Gold II staining. Only the first three significantly improved rotarod motor function. G. lucidum and H. erinaceus recovered weight loss.

preliminary Animal model, chemically induced demyelination, and a 5%-of-diet dose with no human equivalent. Species results are reported as significance calls, not comparable effect sizes.

Yamashina et al., International Journal of Medicinal Mushrooms, 2022 [ref 1]

What makes this study the anchor for cross-species remyelination research is its design: it does not measure a proxy outcome like nerve growth or general anti-inflammatory activity. It measures myelin loss directly, in a model built to mimic the key pathological feature of MS, running multiple species in parallel so they can be compared. No other published study has done this head-to-head comparison.

The limitations are standard for animal models and worth stating plainly: mice are not humans, cuprizone-induced demyelination is not the autoimmune demyelination of MS, and the translational gap from mouse model to clinical benefit has swallowed many promising MS candidates. Adding to that, an endpoint the paper did not report is not evidence of no effect — the study was not designed or powered to establish absence. What it does establish is that the confident claim "Lion's Mane preserved motor function in an MS model" is not supported by the paper people cite for it.

Lion's Mane and the Cells That Build New Myelin

Lion's Mane has the most specific evidence for myelin formation of any medicinal mushroom, and the evidence comes in layers.

The foundation is Kolotushkina et al.'s 2003 in vitro study, which applied Hericium erinaceus extract to cultured cerebellar cells.^[3] Nerve and glial cells grew normally, cell ultrastructure stayed intact, and no toxic effect appeared. The finding that mattered: in the presence of the extract, myelination began earlier than in controls and proceeded at a higher rate. This was not a general neuroprotective observation. The study tracked the timing and rate of myelin genesis specifically, establishing that Lion's Mane has a relationship with the myelination process itself, not just with nerve cell survival.

Huang et al.'s 2021 study in Scientific Reports provided the most mechanistically precise evidence to date, and it went further than cell culture.^[2] The team worked across three systems. In OPC cultures, Lion's Mane mycelium extract (HEM) drove precursor cells to differentiate into mature oligodendrocytes and raised the level of myelin basic protein (MBP) on neuronal fibers. In an ex vivo cerebellar slice system, the overlap between MBP staining and neuronal fibers increased significantly. And in living animals, daily oral administration of HEM to neonatal rat pups for 7 days increased both MBP expression and oligodendrocyte numbers in the corpus callosum.

That in vivo result is important and it is routinely left out of consumer summaries, which describe Huang 2021 as a cell-culture study. It is not only a cell-culture study. But the honest framing cuts both ways: the rat pups were healthy neonatal animals with normally developing nervous systems. The study demonstrates that an orally administered mushroom extract can reach the brain and enhance myelination during normal development. It does not demonstrate re-myelination of a nervous system that has been damaged, because nothing was damaged.

Huang's team also identified the active compounds. Two stood out: HeA, which is erinacine A, a diterpenoid xyloside, and HeS, a sesterterpene built from five isoprene units. A third compound, HeC, was evaluated alongside them. HeA and HeS stimulated MBP expression in oligodendrocytes more potently than the others and increased oligodendrocyte numbers. Identifying specific molecules matters for two reasons. First, it moves the evidence from "mushroom extract did something" to "these molecules drive this effect." Second, it lets researchers study dosing, stability, and extraction with precision — and it means an extract's value depends on whether it actually contains these compounds, which is a manufacturing question, not a species question.

A separate mechanism emerged in Lin et al.'s 2023 study on erinacine S, another compound from Lion's Mane mycelium.^[4] Erinacine S enhanced neurite outgrowth, promoted post-injury axon regeneration in peripheral nervous system neurons, and improved regeneration of CNS neurons growing on inhibitory substrates. RNA sequencing traced the effect to accumulation of neurosteroids in the neurons, confirmed by ELISA and inhibitor assays.

This is worth flagging carefully, because it is easy to over-read. Erinacine S is an axon regeneration finding — regrowing the nerve fiber itself. The study did not measure myelination, MBP, or oligodendrocytes. Axon regrowth and myelin rebuilding are related repair processes but they are not the same thing, and treating this as a third remyelination pathway overstates what was shown. It is better understood as a distinct neural repair mechanism that happens to live in the same mushroom.

For the NGF pathway specifically, which explains how Lion's Mane stimulates the growth of nerve connections rather than the myelin that wraps them, the hericenones and NGF synthesis article covers that mechanism in depth. For the full Lion's Mane evidence profile in the MS context, including the clinical translation question, see Lion's Mane for MS: The Most Promising Mushroom for Myelin Repair.

Reishi: No Remyelination Mechanism, But the Longest Reach

Reishi (Ganoderma lucidum) appears frequently in MS discussions, and the standard framing is that it is the "anti-inflammatory one" while Lion's Mane is the "repair one." That framing is half right and it undersells Reishi's actual record.

Reishi has no evidence for promoting OPC maturation or new myelin formation. Nothing in the literature shows it building myelin. But it is the only mushroom species that has produced benefit in both rodent MS models.

In Yamashina's cuprizone study, G. lucidum was the only one of the four species to hit all three endpoints: it suppressed demyelination, significantly improved motor function, and recovered weight loss.^[1]

Then in 2026, Zhang et al. tested G. lucidum in experimental autoimmune encephalomyelitis (EAE), the standard model for the immune-mediated demyelination that actually characterizes human MS.^[7] Early preventive administration significantly reduced disease severity, inflammatory infiltration, and demyelination in the spinal cord. Mechanistically, it suppressed microglial activation and pushed microglia toward an anti-inflammatory M2-like phenotype. In parallel cell experiments, Reishi scavenged superoxide, nitric oxide, and peroxynitrite, and reduced IL-1β, TNF-α, IL-6, COX2, and iNOS in stimulated microglial cells, working through inhibition of the NF-κB/STAT3 pathway.

Autoimmune Model

Zhang et al. (2026) · Chinese Medicine

Population

Mice with experimental autoimmune encephalomyelitis (EAE); plus LPS-stimulated microglial cells in vitro

Intervention

Early preventive administration of Ganoderma lucidum

Comparator

Untreated EAE controls

Finding

Reduced disease severity, inflammatory infiltration, demyelination, and microglial activation in the spinal cord, with a shift toward anti-inflammatory M2-like microglia. In vitro, scavenged reactive oxygen and nitrogen species and downregulated IL-1β, TNF-α, IL-6, COX2 and iNOS via NF-κB/STAT3 inhibition.

positive Preventive dosing in an animal model — administration began before disease established, which is not how a patient would encounter it. No myelin-formation endpoint was measured.

Zhang et al., Chinese Medicine, 2026 [ref 7]

Note the caveat inside that result: the administration was preventive, started early rather than applied to established disease. That is a meaningful gap between the model and the clinical situation, where someone already has MS.

Still, the picture that emerges is the reverse of the popular framing. The mushroom with the deepest remyelination mechanism has never been tested for myelin formation in a disease model. The mushroom with no remyelination mechanism has cleared both disease models.

Two Claims, Opposite Reach

Building Myelin and Protecting Myelin Are Not the Same Evidence

Both tracks are scored on the same six rungs, from cell culture up to human trials. The mushroom with the best remyelination mechanism has travelled the shortest distance toward MS. The mushroom with no remyelination mechanism has travelled the furthest.

Build new myelin

Lion's Mane (Hericium erinaceus)

1. Cell culture — evidence exists

   OPCs matured to oligodendrocytes; MBP increased [ref 2]. Myelination began earlier and ran faster than controls [ref 3]

2. Ex vivo tissue — evidence exists

   MBP/neuronal-fibre overlap rose in cerebellar slices with HeA and HeS [ref 2]

3. Healthy rodent in vivo — evidence exists

   7 days oral HEM in neonatal rat pups raised MBP and oligodendrocyte counts in corpus callosum [ref 2]

4. Rodent MS model — chemical — no evidence

   Fed in the cuprizone study, but myelin FORMATION was never the endpoint [ref 1]

5. Rodent MS model — autoimmune — no evidence

   Not tested

6. Human trial — no evidence

   Not tested

Deepest mechanism, shortest reach into disease. Every myelin-formation result comes from a normally developing nervous system, not a demyelinating one.

Protect existing myelin

Reishi (Ganoderma lucidum)

1. Cell culture — evidence exists

   Scavenged superoxide, nitric oxide and peroxynitrite; lowered IL-1b, TNF-a, IL-6, COX2, iNOS in stimulated microglia [ref 7]

2. Ex vivo tissue — no evidence

   Not tested

3. Healthy rodent in vivo — no evidence

   Not tested

4. Rodent MS model — chemical — evidence exists

   Suppressed demyelination, improved rotarod motor function, reversed weight loss [ref 1]

5. Rodent MS model — autoimmune — evidence exists

   Reduced disease severity, inflammatory infiltration and demyelination; drove microglia toward M2 phenotype [ref 7]

6. Human trial — no evidence

   Not tested

No remyelination mechanism at all, yet the only species to clear both rodent MS models — including the autoimmune one that actually mirrors human MS.

Neither track reaches the top rung. No mushroom of any species has been tested in people with MS with a myelin endpoint, so the two columns are a map of preclinical reach — not a ranking of clinical usefulness.

Sources: Huang et al., Scientific Reports, 2021 [ref 2]; Kolotushkina et al., Fiziolohichnyi Zhurnal, 2003 [ref 3]; Yamashina et al., International Journal of Medicinal Mushrooms, 2022 [ref 1]; Zhang et al., Chinese Medicine, 2026 [ref 7].

The Immune Direction Problem

There is a complication in the Reishi story that most coverage skips, and it deserves its own treatment because it runs opposite to the usual "immune modulation" reassurance.

Lin's 2005 review in the Journal of Pharmacological Sciences is the paper most often cited for Ganoderma's immune effects. What it actually documents is that G. lucidum polysaccharides promote immune function across the board: antigen-presenting cell function, the mononuclear phagocyte system, humoral immunity, and cellular immunity.^[6] The review is explicit that whole-animal experiments and evidence-based clinical trials were still needed to establish these mechanisms.

That is an immune-enhancing profile. MS is an autoimmune disease in which the immune system attacks the patient's own myelin. A 2025 review of medicinal mushrooms in MS lists "increased immune system performance" and "increased B and T cells" among the mechanisms proposed to explain mushroom benefit in MS.^[9] In an autoimmune context, that proposed mechanism should raise a question rather than settle one.

Fact Check

Myth vs. evidence

The claim

“Reishi calms the overactive immune system, which is exactly what an autoimmune disease like MS needs.”

Generalized from the phrase 'immunomodulatory', which gets read as 'immune-calming' in wellness writing.

What research shows

Overstated

The most-cited review of Ganoderma immunology describes its polysaccharides as promoting antigen-presenting cell function, the mononuclear phagocyte system, humoral immunity and cellular immunity — enhancement, not suppression [ref 6]. Reviews of mushrooms in MS likewise list increased immune performance and increased B and T cells among the proposed mechanisms [ref 9].

Reishi's benefit in the EAE model ran through microglia — dampening CNS-resident inflammatory cells and oxidative stress via NF-κB/STAT3 — rather than through broad immunosuppression [ref 7]. So the animal result and the immune-enhancing profile are not contradictory, but 'it calms autoreactive T-cells' is a claim nobody has demonstrated.

Lin, J Pharmacol Sci, 2005 [ref 6]; Zhang et al., Chinese Medicine, 2026 [ref 7]; Pourmohammadi et al., Fitoterapia, 2025 [ref 9]

The resolution is that "immunomodulatory" is not a direction. Reishi's demonstrated benefit in EAE came from acting on microglia and oxidative stress inside the central nervous system, which is a different lever than systemically suppressing autoreactive lymphocytes. The animal data is real. The mechanism people assume is behind it is not the mechanism that was shown.

For the specific regulatory T-cell expansion mechanism and its relevance to MS autoimmunity, the reishi and autoimmune MS article covers that evidence in depth.

Autoimmune Context

Moderate

Immune-Stimulating Supplements in an Autoimmune Disease

Concern

Most medicinal mushroom polysaccharides are characterized in the literature as immune-enhancing, and reviews of mushrooms in MS explicitly list increased B and T cell activity among their proposed mechanisms. In a disease driven by immune attack on the patient's own myelin, stimulating immune activity is not self-evidently beneficial.

What the research says

No study has tested whether mushroom supplementation worsens autoimmune activity in people with MS, and no study has tested how mushroom immunomodulation interacts with the immunosuppressive and immunomodulatory DMTs most MS patients take. The absence of reported harm in preclinical work is not the same as demonstrated safety in medicated patients.

Particularly relevant for: People with MS, particularly anyone on interferon-beta, natalizumab, ocrelizumab, fingolimod, or other disease-modifying therapy

What to do

Discuss any mushroom supplement with the neurologist managing your MS before starting it. This article is research education, not medical advice, and nothing here should be used to start, stop, or change a treatment.

Lin, J Pharmacol Sci, 2005 [ref 6]; Pourmohammadi et al., Fitoterapia, 2025 [ref 9]

Cross-Species Comparison: Where Each Mushroom Fits the Evidence

Phan et al.'s 2015 review in Critical Reviews in Biotechnology surveyed over 20 brain-improving culinary-medicinal mushrooms and at least 80 bioactive metabolites isolated from them, spanning Hericium erinaceus, Ganoderma lucidum, Sarcodon species, Antrodia camphorata, Pleurotus giganteus, Lignosus rhinocerotis, and Grifola frondosa.^[5] The documented effects were neurite outgrowth stimulation, NGF synthesis, reduction of beta-amyloid neurotoxicity, anti-acetylcholinesterase activity, antioxidant and anti-neuroinflammatory effects. The review's own conclusion is that it focuses on in vitro evidence and that human clinical trials are needed — a framing worth carrying into the table below.

The comparison is structured by mechanistic specificity, from most directly relevant to remyelination to least:

The table reveals something the usual discussion flattens: "mushrooms and MS" conflates at least three different claims. Some mushrooms may help build new myelin (Lion's Mane). Some may protect existing myelin from immune attack (Reishi, and on this evidence king oyster and enoki too). Some have general neuroprotective and antioxidant activity with no MS-model data at all (Cordyceps, whose most MS-adjacent finding is that it suppresses immune activation triggered by myelin oligodendrocyte glycoprotein, the peptide used to induce EAE).^[8] These are not interchangeable. "Good for the nervous system" does not translate to "remyelinating."

Evidence Reach

1. Cell and tissue studiescompleted

   OPC maturation, MBP increase, earlier and faster myelination, identified active compounds (HeA, HeS) — Kolotushkina 2003, Huang 2021

2. Animal studiescurrent

   Myelination enhanced in healthy neonatal rat brain (Huang 2021); demyelination suppressed in cuprizone model across four species (Yamashina 2022); severity and demyelination reduced in autoimmune EAE model (Zhang 2026)

3. Case reports in MS patientsmissing

   None published for any mushroom with a myelin endpoint

4. Small human trialsmissing

   No trial has tested a mushroom supplement in people with MS

5. Large randomized trialsmissing
6. Meta-analysismissing

The field has cleared the cell-study rung convincingly and is working through the animal rung, now including the autoimmune model that best mirrors human MS. It has not taken a single step into human MS. Every clinical claim you encounter is extrapolating across that gap.

Kolotushkina 2003 [ref 3]; Huang 2021 [ref 2]; Yamashina 2022 [ref 1]; Zhang 2026 [ref 7]

The cross-species mushroom research in Alzheimer's article documents an identical pattern across a different neurodegenerative condition: Lion's Mane and Reishi have distinct, non-overlapping mechanisms that are both relevant but in different ways.

For readers interested in how mushroom neuroprotection extends to traumatic injury, the same mechanistic framework applies in mushrooms for traumatic brain injury research.

Honest Limitations: Preclinical Data in a Clinical Disease

Every study cited in this article is preclinical. That phrase requires unpacking, because it gets treated as a minor caveat when it is the central limitation.

Preclinical means cell culture, tissue, or animal experiments. The distribution matters. The direct myelination finding (Kolotushkina 2003) is cell culture. The OPC maturation work (Huang 2021) spans cell culture, ex vivo tissue, and living rat pups — but healthy ones, with no myelin damage to repair. The neurosteroid pathway (Lin 2023) is axon regeneration in cultured neurons, not myelination. Yamashina 2022 reaches an animal MS model, but a chemically induced one. Zhang 2026 reaches the autoimmune EAE model, which is the closest analogue to human MS pathology available, but with preventive dosing in mice.

No randomized clinical trial has tested any medicinal mushroom supplement in MS patients and measured myelin repair outcomes. Not one. The comprehensive reviews are explicit about this: Phan 2015 states directly that its evidence base is in vitro and that human trials are needed.^[5] The 2025 mushrooms-in-MS review frames medicinal mushrooms as a promising future direction, not an established one.^[9]

Dose translation is its own problem, and it is larger than usual here. Yamashina's mice ate a diet that was 5% mushroom powder by weight for five weeks. There is no honest way to convert that into a capsule count. Huang's rat pups received a mycelium extract, which is a different material from a fruiting body powder, and a different material again from most commercial supplements — whose actual erinacine A and HeS content is rarely disclosed and rarely verified.

The additional challenge is that MS is a condition many patients manage with powerful immunomodulatory medications. Mushroom compounds have their own immunomodulatory properties, which as discussed above tend toward immune enhancement. The interaction between these two things in a living MS patient on medication is entirely unstudied. That is a genuine safety knowledge gap, not a precautionary formality. The mushroom supplements and MS safety considerations article addresses this in full.

The honest position: the preclinical evidence for Lion's Mane and myelin formation is mechanistically specific, compound-level, and now extends into living animals. The preclinical evidence for Reishi and myelin protection has reached both rodent MS models. That is a more meaningful foundation than no evidence, and it is a better foundation than most supplement categories can claim. It is not a foundation for confident clinical statements about remyelination in people with MS, and this article is not medical advice.

The Bottom Line

Lion's Mane has the most specific preclinical evidence for myelin formation of any medicinal mushroom: myelination began earlier and ran faster in cerebellar cell culture (Kolotushkina 2003), and oligodendrocyte precursor cells matured with increased myelin basic protein in culture, in ex vivo slices, and in the brains of neonatal rat pups given the extract orally (Huang 2021), with HeA (erinacine A) and HeS identified as the active compounds. But in Yamashina et al.'s 2022 cuprizone MS mouse model — the only head-to-head test of four species — Lion's Mane suppressed demyelination yet was the one species that did not significantly improve motor function, while Reishi hit all three endpoints. Reishi, despite having no evidence for building new myelin, is also the only species to show benefit in the autoimmune EAE model (Zhang 2026), acting through microglial polarization and oxidative-stress reduction rather than the immune suppression people assume. No clinical trial has tested any mushroom in MS patients with a myelin endpoint.

Frequently Asked Questions

Which mushroom is best for myelin repair?

It depends which claim you mean. For building new myelin, Lion's Mane has the only real evidence: it accelerated myelination in cell culture (Kolotushkina 2003) and matured oligodendrocyte precursor cells with increased myelin basic protein in culture, ex vivo tissue, and the brains of neonatal rat pups (Huang 2021). For protecting existing myelin in an actual MS model, Reishi has the better record — it was the only species of four to improve demyelination, motor function, and weight loss in the cuprizone mouse model (Yamashina 2022), and the only one to also reduce demyelination in the autoimmune EAE model (Zhang 2026). No mushroom has been shown to repair myelin in human clinical trials.

Do mushrooms help remyelinate nerve fibers?

In laboratory settings, Lion's Mane extract accelerated myelination in cerebellar cell culture and caused oligodendrocyte precursor cells to mature into myelin-producing cells, with more myelin basic protein appearing on nerve fibers. The same study found increased myelin basic protein and oligodendrocytes in neonatal rat brain after 7 days of oral dosing — but those were healthy animals, so it demonstrates enhanced myelination, not repair of damage. In the 2022 Yamashina mouse study, four mushroom species suppressed demyelination in an MS-mimicking model, which is prevention of myelin loss rather than rebuilding of lost myelin. No clinical trials have tested mushroom supplements for remyelination in MS patients.

What does research show about mushrooms and remyelination?

Three tiers of preclinical evidence exist. First, in vitro and ex vivo work shows Lion's Mane accelerates myelination and drives oligodendrocyte precursor cell maturation with measurable increases in myelin basic protein, with HeA (erinacine A) and HeS identified as the active compounds (Huang 2021, Kolotushkina 2003). Second, animal work: Lion's Mane increased myelination in healthy neonatal rat brain (Huang 2021); four species suppressed demyelination in a cuprizone-induced MS mouse model, though only three improved motor function (Yamashina 2022); and Reishi reduced disease severity, inflammatory infiltration and demyelination in the autoimmune EAE model (Zhang 2026). Third, broad reviews document antioxidant and anti-neuroinflammatory effects across species but conclude human trials are still needed (Phan 2015). No human clinical data exists for any of it.

Can any mushroom regenerate myelin?

No mushroom has been demonstrated to regenerate myelin in humans. In cell culture, Lion's Mane mycelium extract caused oligodendrocyte precursor cells to mature into myelin-producing cells and measurably increased myelin basic protein on neuronal fibers (Huang 2021). The same study raised myelin basic protein in living rat brain after oral dosing, which is the strongest evidence any mushroom has for affecting myelin in an intact nervous system — but the animals were healthy, so this shows enhanced myelin formation during normal development, not regeneration after damage. Whether any of this translates to a damaged human nervous system remains untested.

What mushrooms help with nerve damage?

Lion's Mane has the broadest set of nerve repair mechanisms: NGF induction supporting neuron survival and connectivity, oligodendrocyte precursor maturation relevant to myelin, and a neurosteroid pathway that promotes axon regeneration after injury (Lin 2023). Reishi acts on inflammation and oxidative stress and has reduced demyelination in both rodent MS models. Cordyceps has antioxidant and neuroprotective activity but no MS-model data. All of this evidence is preclinical. Anyone with MS or another neurological condition should discuss supplements with their treating clinician first, since mushroom polysaccharides are generally characterized as immune-enhancing and interactions with MS disease-modifying therapies have never been studied.

Sources & References

1. 1RTHM-01637·Yamashina, Kota et al. (2022). “Suppressive Effect of Fruiting Bodies of Medicinal Mushrooms on Demyelination and Motor Dysfunction in a Cuprizone-Induced Multiple Sclerosis Mouse Model..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
2. 2RTHM-00692·Huang, Hui-Ting et al. (2021). “Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein..” Scientific reports.Study breakdown →PubMed →↩
3. 3RTHM-00058·Kolotushkina, E V et al. (2003). “The influence of Hericium erinaceus extract on myelination process in vitro..” Fiziolohichnyi zhurnal (Kiev.Study breakdown →PubMed →↩
4. 4RTHM-01734·Lin, Chun-Yu et al. (2023). “Erinacine S from Hericium erinaceus mycelium promotes neuronal regeneration by inducing neurosteroids accumulation..” Journal of food and drug analysis.Study breakdown →PubMed →↩
5. 5RTHM-00397·Phan, Chia-Wei et al. (2015). “Therapeutic potential of culinary-medicinal mushrooms for the management of neurodegenerative diseases: diversity, metabolite, and mechanism..” Critical reviews in biotechnology.Study breakdown →PubMed →↩
6. 6RTHM-00084·Lin, Zhi-Bin (2005). “Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum..” Journal of pharmacological sciences.Study breakdown →PubMed →↩
7. 7RTHM-02429·Zhang, L et al. (2026). “Ganoderma lucidum mediates microglial polarization and ameliorates experimental autoimmune encephalomyelitis by reducing oxidative stress and inhibiting NF-κB/STAT3 pathway..” Chinese medicine.Study breakdown →PubMed →↩
8. 8RTHM-02247·Yang, Eun-Ju et al. (2026). “An Immunomodulatory Mushroom, Cordyceps militaris, and Its Constituents: A Review of In Vitro/In Vivo Studies and Clinical Trials..” Phytotherapy research : PTR.Study breakdown →PubMed →↩
9. 9RTHM-02163·Pourmohammadi, Golchehr et al. (2025). “New approach of using medicinal mushrooms for managing and curing multiple sclerosis..” Fitoterapia.Study breakdown →PubMed →↩